Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial is a research paper published in The Journal of Infectious Diseases (2024). On theSindex it has a DataRank of 0.165. It has been cited 2 times, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →NIAID NIH HHS
Grant: UM1 AI068636
NIAID NIH HHS
Grant: UM1 AI069412
NIAID NIH HHS
Grant: UM1 AI069423
NIAID NIH HHS
Grant: UM1 AI106701
NIAID NIH HHS
Grant: UM1 AI069432
National Institutes of Health
Grant: UM1AI068634
NIAID NIH HHS
Grant: UM1 AI069424
NIAID NIH HHS
Grant: U01 AI069423
NCATS NIH HHS
Grant: UL1 TR001881
Regeneron Pharmaceuticals
SAB Biotherapeutics
National Institute of Allergy and Infectious Diseases
MeSH Terms
Keywords